Uber Technologies Inc. (NYSE: UBER) is set to report its third-quarter earnings results on Monday, November 4, after the market closes. The results will be weighed down by cost pressure, which has been increasing more-than-expected due to driver incentives and investments in the business.
The company has been struggling to carry the top-line growth to the bottom line due to mounting expenses. Also, concerns have been mounting about the profitability and growth in the present times as the company is operating in industries that have exponential growth in the future.
Uber will continue to incur losses in the near term as a result of expected substantial increases in operating expenses, due to its investments in the daily running of the business. The company has been facing hurdles about the introduction of new products such as UberPOOL that generates lower gross bookings per trip or a lower take rate instead of value addition.
The gross bookings are an indication of the scale of Uber’s current platform, which ultimately impacts revenue. The company generates substantially all of its revenue from fees paid by drivers and restaurants for use of its platform. At the end of the second quarter of 2019, Uber had 99 million active users on its platforms compared to 57 million in the second quarter of 2017.
Analysts expect the company to report a loss of $0.81 per share on revenue of $3.69 billion for the third quarter. For the second quarter, the ridesharing firm reported a wider loss as excess driver incentives drove costs and expenses higher. The top line increased by 14% year-over-year helped by strong contributions from Uber Eats and other bets.
Read: Lyft Q3 earnings review
The company’s stock has remained a concern for investors as the shares have fallen over 24% since it went public in May. The stock has climbed to reach $47.08 on June 28 but taken the downward path to reach the lowest of $28.31 on October 2.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
